表紙
市場調査レポート

免疫測定・遺伝子プローブ用の標識薬剤と結合薬剤

Labeling and Linkage Agents for Immunoassays and Gene Probes

発行 BCC Research 商品コード 223023
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
免疫測定・遺伝子プローブ用の標識薬剤と結合薬剤 Labeling and Linkage Agents for Immunoassays and Gene Probes
出版日: 2011年10月31日 ページ情報: 英文
概要

当レポートでは、免疫測定・遺伝子プローブ用の標識薬剤と結合薬剤市場について概説し、2009年と2010年の実績、2011年〜2016年の予測、用途別、地域別需給シナリオ、および市場に参入する主な企業の包括的プロファイルをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 技術概要

  • 免疫測定技術
  • 定性的・定量的免疫測定法
  • 免疫測定技術の応用
  • 従来方式と免疫測定の比較
  • 免疫測定方法
  • 免疫測定技術
  • 遺伝子プローブ技術 (核酸アッセイ)
  • 患者標本における腫瘍遺伝子評価に用いられるDNAプローブ
  • 遺伝子プローブ
  • 分子標識
  • 食品の細菌汚染検出
  • チップベースの核酸アッセイ
  • レポーター遺伝子アッセイ

第4章 プローブと関連化学物質の概要

  • 放射性化合物
  • 酵素/酵素基質
  • 蛍光化合物
  • 化学発光化合物
  • 遺伝子プローブ
  • 酵素結合免疫吸着剤アッセイ手順
  • 分子画像および光画像
  • 光画像
  • 化学発光化合物
  • フローサイトメトリ

第5章 応用別免疫剤市場、分子診断

  • 免疫原性プローブ市場の変化
  • ポイントオブケア検査
  • 感染病検査
  • 法医学、バイオテロ、実父鑑定検査
  • 合併・買収
  • 世界の免疫測定と分子診断活動

第6章 企業プロファイル

  • 市場シェアと主要企業
  • ABBOTT LABORATORIES
  • AFFYMETRIX
  • BECKMAN-COULTER
  • BIOMERIEUX
  • BIO-RAD LABORATORIES
  • GE HEALTHCARE LIFE SCIENCES
  • GENENTECH, INC.
  • GEN-PROBE INCORPORATED
  • LIFE TECHNOLOGIES
  • MILLIPORE CORPORATION (MERCK KGAA)
  • QIAGEN, INC.
  • ROCHE DIAGNOSTICS
  • SIGMA-ALDRICH, USA
  • THERMO FISHER LIFE SCIENCES

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO038C

Abstract

REPORT HIGHLIGHTS

THIS REPORT CONTAINS:

  • An overview of the technological developments in the market for labeling and linkage agents for immunoassays and gene probes
  • Analyses of global market trends, with data from 2009 and 2010, estimates for 2011, and projections of compound annual growth rates (CAGRs) through 2016
  • The most current and reliable information on consumption of probes and related chemicals in enzyme immunoassay
  • Estimates of the global supply-and-demand scenario broken down by applications and regions
  • Comprehensive profiles of major companies involved in the industry and their market shares.

image1

REPORT SCOPE

INTRODUCTION

OBJECTIVES AND GOAL OF THE STUDY

This study provides the reader with a detailed analysis of the current application and consumption and future growth potential of immunoagents, gene probes, and molecular diagnostics. This study also analyzes the recent technological developments, future industry trends, and emerging business opportunities. Such information will facilitate the investment decisions and strategic planning for business managers.

Immunoassays are used to determine antibody or antigen levels in a variety of disease situations. Gene probes explore the DNA makeup of microorganisms causing infection and of the gene structure of cellular mutations involved in cancer diabetes, coronary disease, etc. Molecular diagnostics is an emerging science that studies cellular biomarkers that are related to gene expression and that also develops assays to serve as companion diagnostic tests to allow physicians to better structure treatment of diseases.

Major objectives of this study are to:

Assess the technology developments and how they will impact this industry. Identify the driving forces for demand. Make available the most current and reliable information on consumption of probes and related biomolecules in enzyme immunoassays. Estimate a global supply and demand scenario broken down by applications and regions. Project the growth rate in demand. Estimate the projected demand and supply by applications and regions through 2016. Profile major companies involved in this business and their market shares.

REASONS FOR DOING THE STUDY

The segment of the diagnostic industry using immunoassays, gene probes, and molecular diagnostics has developed rapidly as scientific understanding of these systems has advanced in the past decade. This industry is undergoing rapid changes driven by the ongoing progress in biotechnology and medicine. This area is now experiencing major research and development (R&D) initiatives, which are leading to the development of new products, and to improvements in the sensitivities and performance of existing immunoassay products. This has direct impact on the demand, consumption, and future growth of the labeling and immunoagents, gene probes, and the developing market of molecular diagnostics.

This report provides a current and comprehensive global report on the scientific fields that make up diagnostic tests. This study provides a comprehensive analysis of the underlying influences brought about by rapid developments in diagnostic products, changes in governmental regulations, and the evolving economies of countries such as China, India, the Pacific Rim, Australia, Brazil, Russia, and the Middle East.

This study also looks at major global players in this field and provides an insight into their performance; in addition, it anticipates involvement in future technological trends and potential investment opportunities in the field.

SCOPE OF STUDY

The Scope of this study is to outline the international supply and demand for compounds used in immunoassays and in probes, including gene probes, and related chemicals employed in diagnostic tests and in the detection of various antigens/analytes. This study excludes separation and purification applications, which use some of these technologies.

The industries studied in this report are:

  • In vitro diagnostics
    • Research and development laboratories
    • Point-of-Care Testing
      • Doctor's office
      • Private medical laboratories
      • Hospitaal bedside
      • Home
    • Molecular diagnostic testing
  • In vivo diagnostics
    • Immunoassay testing
    • Monoclonal antibody therapy
  • Blood banks
  • Food Safety testing
  • Bioterrorism detection

The large number of biochemical/chemical materials covered in this report is mainly due to the diversity of the immunological tests involved.

The immunological biochemical products covered include:

  • Proteins
  • Antibodies and antigens
  • Cellular components
  • Nucleic acids DNA, RNA
  • Cellular receptors
  • Gene structures
  • Mutated genes involved in diseases

TARGETED AUDIENCE

This study will be of great interest to those involved with the reagents industry, either as manufacturers and suppliers of reagents or as manufacturers of diagnostics/detection tests. It will also be of interest to end users of diagnostics/detection tests as well as to government and regulatory bodies involved in setting standards and tests that use the immunoassay, gene probe, and molecular diagnostic technologies. Research scientists interested in pursuing diagnostics and molecular detections using immunoassays and gene probes also will find this study of value.

Identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities, and insights that provide guidance for sales growth or defensive moves is vital for a variety of readers:

  • Established companies in the industry will benefit from the contents, for corporate strategizing, sales and marketing, business development, and research and development.
  • Emerging companies in this medical diagnostic segment must understand specific opportunities for out-licensing that originate from the elements of differentiation of their product or technology as compared to leading, competitive, and emerging diagnostic tests. Market forecasts can support investment provided a thorough and detailed substantiation is provided for the market forecast.
  • Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry in a product- and company-specific analysis.
  • Equity analysts are provided with detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run. The readers are likely to hold positions in strategic planning, new business development, marketing, product management, sales, including purchasing agents, regulatory officers or analysts/investment advisors. These decision-makers will be better able to plan production, to develop new products, and to find new customers. Planners and marketers will gain insight for company and product positioning. Purchasers will locate new and additional suppliers.

Managers from several related industries will also find valuable information in the report. Distributors, test formulators, traders, and even test laboratory professionals can benefit from a better understanding of the tag/linkage business and how it influences competition in their own industries.

METHODOLOGY

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading researchers in the field. The overall immunology market is comprised of a variety of fast-growing and independent segments. For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment. Within each subsection there is a detailed forecast for each driving mechanism or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the immunoagent, gene probe, and molecular diagnostics areas. Information was gained from scientific publications like Nature Biotech, Genetic and Engineering News, Journal of Experimental Medicine, European Journal of Immunology, Immunology, Clinical and Diagnostic Laboratory Immunology, Immunobiology, Nature Immunology, and others.

Other information was from the World Health Organization (WHO) and other government agencies, literature searches, annual reports, 10-Ks, and others. Population estimates are based on those reported by the international database of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

Major factors impacting the immunoassay, gene probe, and molecular diagnostic supply and demand are discussed. Government regulations, technology developments, patents and international trade are addressed.

ANALYST CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early and mid-stage drug development.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • OBJECTIVES AND GOAL OF THE STUDY
  • REASONS FOR DOING THE STUDY
  • SCOPE OF THE STUDY
  • TARGETED AUDIENCE
  • METHODOLOGY
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table 0 : MARKETS FOR IMMUNOAGENTS, PROBES AND MOLECULAR DIAGNOSTICS, THROUGH 2016
  • Figure 0 : MARKETS FOR IMMUNOAGENTS, PROBES AND MOLECULAR DIAGNOSTICS, 2009-2016

Chapter- 3: TECHNOLOGY OVERVIEW

  • IMMUNOASSAY TECHNOLOGY
  • QUALITATIVE AND QUANTITATIVE IMMUNOASSAYS
  • APPLICATIONS FOR IMMUNOASSAY TECHNIQUES
  • COMPARISON OF IMMUNOASSAYS WITH CONVENTIONAL METHODS
  • METHODS OF IMMUNOASSAYS
  • IMMUNOASSAY TECHNIQUES
  • GENE PROBE TECHNOLOGY (NUCLEIC ACID ASSAYS)
  • DNA PROBES UTILIZED FOR ASSESSING TUMOR GENES IN PATIENT SPECIMENS
  • GENE PROBES
  • MOLECULAR BEACONS
  • DETECTION OF BACTERIAL CONTAMINATION IN FOODS
  • CHIP-BASED NUCLEIC ACID ASSAY
  • REPORTER GENE ASSAY
    • Table 3 : FDA APPROVED NUCLEIC ACID TEST USING DNA PROBE TECHNOLOGIES

Chapter- 4: OVERVIEW OF PROBES AND RELATED CHEMICALS

  • RADIOACTIVE COMPOUNDS
  • ENZYMES/ENZYME SUBSTRATES
  • FLUORESCENT COMPOUNDS
  • CHEMILUMINESCENCE COMPOUNDS
  • GENE PROBES
  • ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) ASSAY PROCEDURES
  • MOLECULAR IMAGING AND OPTICAL IMAGING
  • OPTICAL IMAGING
  • CHEMILUMINESCENT COMPOUNDS
  • FLOW CYTOMETRY

Chapter- 5: MARKETS FOR IMMUNOAGENTS, AND MOLECULAR DIAGNOSTICS BY APPLICATION SECTORS

  • CHANGES IN THE GLOBAL MARKETS FOR IMMUNOGENIC PROBES
  • POINT-OF-CARE TESTS
  • INFECTIOUS DISEASE TESTING
  • FORENSIC, BIOTERRORISM, AND PATERNITY MARKETS
  • MERGERS AND ACQUISITIONS
  • WORLDWIDE IMMUNOASSAY AND MOLECULAR DIAGNOSTICS ACTIVITY
    • Table 56 : DISTRIBUTION OF GLOBAL REVENUES FOR IMMUNOASSAYS, GENE PROBES, AND MOLECULAR DIAGNOSTICS, 2010

Chapter- 6: COMPANY PROFILES

  • MARKET SHARE OF MAJOR COMPANIES
  • ABBOTT LABORATORIES
  • AFFYMETRIX
  • BECKMAN-COULTER
  • BIOMERIEUX
  • BIO-RAD LABORATORIES
  • GE HEALTHCARE LIFE SCIENCES
  • GENENTECH, INC.
  • GEN-PROBE INCORPORATED
  • LIFE TECHNOLOGIES
  • MILLIPORE CORPORATION (MERCK KGAA)
  • QIAGEN, INC.
  • ROCHE DIAGNOSTICS
  • SIGMA-ALDRICH, USA
  • THERMO FISHER LIFE SCIENCES

List of Tables

  • Summary Table : MARKETS FOR IMMUNOAGENTS, PROBES AND MOLECULAR DIAGNOSTICS, THROUGH 2016
  • Table 1 : COMMONLY USED CHEMILUMINESCENT COMPOUNDS
  • Table 2 : COMMON MOLECULAR BEACON AND QUENCHER COMBINATIONS
  • Table 3 : FDA APPROVED NUCLEIC ACID TEST USING DNA PROBE TECHNOLOGIES
  • Table 4 : PROPERTIES OF RADIOACTIVE ISOTOPES USED IN RADIOACTIVE LABELED PROBES
  • Table 5 : RADIONUCLIDES COMMONLY USED FOR DIAGNOSTIC IMAGING
  • Table 6 : USE OF RADIOACTIVE PROBES - THYROID IMAGING
  • Table 7 : ADDITIONAL USE OF ISOTOPES IN THYROID SCANNING
  • Table 8 : RADIO-LABELED ANTIBODIES FOR DIAGNOSIS OF SPECIFIC CANCE8S
  • Table 9 : USE OF RADIOACTIVE PROBES IN DIAGNOSIS OF THYROIDISM
  • Table 10 : USE OF RADIOACTIVE PROBES - RADIO-CARDIOGRAPHY
  • Table 11 : USE OF RADIOACTIVE PROBES - TUMOR IMAGING
  • Table 12 : USE OF RADIOACTIVE PROBES - CANCER TREATMENT
  • Table 13 : USE OF RADIOACTIVE PROBES - DETERMINATION OF CIRCULATION RED CELL MASS/PLASMA VOLUME
  • Table 14 : USE OF RADIOACTIVE PROBES - DETERMINATION OF BLOOD FLOW
  • Table 15 : USE OF RADIOACTIVE PROBES - STOMACH IMAGING
  • Table 16 : USE OF RADIOACTIVE PROBES - TREATMENT OF LEUKEMIAS
  • Table 17 : USE OF RADIOACTIVE PROBES - STUDY OF GASTROINTESTINAL PROTEIN LOSS
  • Table 18 : USE OF RADIOACTIVE PROBES - SCANNING LUNGS/BRAIN
  • Table 19 : USE OF RADIOACTIVE PROBES - MYOCARDIAL STUDIES
  • Table 20 : USE OF RADIOACTIVE PROBES - HEART IMAGING
  • Table 21 : USE OF RADIOACTIVE PROBES - CEREBRAL PERFUSION IMAGING
  • Table 22 : USE OF RADIOACTIVE PROBES - BONE IMAGING
  • Table 23 : USE OF RADIOACTIVE PROBES - LUNG IMAGING
  • Table 24 : USE OF RADIOACTIVE PROBES - RENAL IMAGING
  • Table 25 : USE OF RADIOACTIVE PROBES - MALIGNANT AND INFLAMMATORY REGIONS
  • Table 26 : USE OF RADIOACTIVE PROBES - AUTORADIOGRAPHY
  • Table 27 : COMMON TYPES OF ELISA ASSAY
  • Table 28 : ENZYMES AND SUBSTRATES USED IN ELISA ASSAYS
  • Table 29 : COMMONLY USED FLUOROPHORES IN FIA
  • Table 30 : FLUOROPHORES AND THEIR APPLICATIONS
  • Table 31 : FLUOROPHORES AND THEIR APPLICATIONS
  • Table 32 : RADIO-PROBES USED IN MOLECULAR IMAGING
  • Table 33 : COMMONLY USED CHEMILUMINESCENT COMPOUNDS
  • Table 34 : BLOTTING METHODS DEVELOPED FOR BIOMOLECULAR SPECIES
  • Table 35 : FLUOROCHROME DYES USED IN MOLECULAR DIAGNOSTICS AND MOLECULAR PROBES
  • Table 36 : LIST OF FDA-APPROVED DRUGS THAT HAVE BIOMARKER INFORMATION INCLUDED IN THEIR LABELING
  • Table 37 : GLOBAL MARKET FOR IMMUNOAGENTS, PROBES, AND MOLECULAR DIAGNOSTICS BY APPLICATION SECTORS, THROUGH 2016
  • Table 38 : DIAGNOSTIC CATEGORIES FOR FAILED DRUG CLINICAL TRIALS IN PERIOD 2008-2016
  • Table 39 : GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, THROUGH 2016
  • Table 40 : GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS INCLUDING MOLECULAR ANTIBODY THERAPY, THROUGH 2016
  • Table 41 : REGIONAL SHARE OF THE MARKET FOR IMMUNOAGENTS, PROBES, AND MOLECULAR DIAGNOSTICS, THROUGH 2016
  • Table 42 : FDA CRITERIA FOR CATEGORIZING POTENTIAL POC TEST
  • Table 43 : TYPES OF POC TESTS WITH AUTOMATIC WAIVED STATUS
  • Table 44 : GLOBAL REVENUES FROM POC TESTING, THROUGH 2016
  • Table 45 : GLOBAL MARKET FOR IN VITRO DIAGNOSTICS POC TESTS BY APPLICATION SECTORS, THROUGH 2016
  • Table 46 : GLOBAL DISTRIBUTION OF IN VITRO DIAGNOSTICS POC TESTS BY REGION, 2010
  • Table 47 : GLOBAL REVENUES FROM MOLECULAR DIAGNOSTICS TESTS, THROUGH 2016
  • Table 48 : CURRENT FDA APPROVED MOLECULAR DIAGNOSTICS TESTS
  • Table 49 : MOLECULAR DIAGNOSTICS SYSTEMS CURRENT IN COMMERCE 2011
  • Table 50 : FDA-APPROVED INFECTIOUS DISEASE TESTS
  • Table 51 : NUMBER OF U.S. PATENTS ISSUED FOR MOLECULAR DIAGNOSTICS DURING THE PERIOD, THROUGH 2010
  • Table 52 : NUMBER OF U.S. PATENTS ISSUED TO UNIVERSITIES DURING THE PERIOD, THROUGH 2010
  • Table 53 : PHARMACEUTICAL AND BIOTECHNOLOGY MERGERS AND ACQUISITIONS IN 2010
  • Table 54 : MAJOR ACQUISITIONS IN BIOPHARMACOLOGY/BIOTECHNOLOGY IN 2009
  • Table 55 : MAJOR MERGER AND ACQUISITION ACTIVITY IN BIOTECH INDUSTRY DURING THE PERIOD 2005 THROUGH 2008
  • Table 56 : DISTRIBUTION OF GLOBAL REVENUES FOR IMMUNOASSAYS, GENE PROBES, AND MOLECULAR DIAGNOSTICS, 2010
  • Table 57 : MARKET SHARE OF MAJOR COMPANIES IN THE IMMUNOASSAY AND MOLECULAR DIAGNOSTICS AREAS, 2010
  • Table 58 : REPRESENTATIVE IMMUNOASSAY PRODUCTS AND AUTOMATED SYSTEMS (ARCHITECT SERIES) FOR THEIR ANALYSIS
  • Table 59 : BIOMERIEUX BIOMARKERS
  • Table 60 : GENENTECH PRODUCTS IN PRODUCTION
  • Table 61 : GEN-PROBE STANDARDIZED ANTIBODIES
  • Table 62 : LIFE TECHNOLOGIES' CELL-LIGHT MOLECULAR SIGNALING DYES
  • Table 63 : ROCHE DIAGNOSTIC TESTS
  • Table 64 : MAJOR PRODUCT OFFERINGS OF SIGMA-ALDRICH
  • Table 65 : CUSTOMIZED ANTIBODY PRODUCTION PROCESS OF THERMO FISHER LIFE SCIENCES

List of Figures

  • Summary Figure : MARKETS FOR IMMUNOAGENTS, PROBES AND MOLECULAR DIAGNOSTICS, 2009-2016
Back to Top